跳至主要内容
临床试验/TCTR20210525007
TCTR20210525007尚未招募4 期

Effect of MK-7 supplementation to dp-ucMGP levels in chronic hemodialysis patients receiving phosphate binders

The College of Pharmacotherapy of Thailand0 个研究点目标入组 30 人开始时间: 2021年5月25日最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 N/A (No limit)(—)
性别
All

入选标准

  • 1.Thai adults chronic hemodialysis patients
  • 2.Receiving monotherapy of phosphate binder

排除标准

  • 1.History of cardiovascular diseases
  • 2.History of coagulation defects
  • 3.History of malignancy
  • 4.Presence of lipid absorption disorders
  • 5.Elevated liver enzymes, above 3 times the upper limit of normal
  • 6.Serum albumin less than 2.5 g/dL
  • 7.Body mass index less than 18 kg/m2
  • 8.VitaminK antagonists treatment within 90 days prior to recruitment
  • 9.Concomitant drugs affect vitaminK levels e.g. carbamazepine, cholestyraine, lamotrigine, menadione, menaquinone, orlistat, oxcarbamazepine, phenobarbital, phenytoin, phytomenadione
  • 10.Receiving antibiotics at least 10 days during recruitment
  • 11.Phosphate binders dose adjustment within 30 days prior to recruitment
  • 12.Hypersensitivity to menaquinone or any component of the formulation
  • 13.Medication adherence less than 80%
  • 14.Refuse to participate

研究者

发起方
The College of Pharmacotherapy of Thailand

相似试验